Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | ADH5 | P11766 | 3/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7464609 | 0.84 | RXRA (0.46) | NOTUMCD38ADH5 | |
| SCHEMBL5211444 | 0.81 | CYP11B1 (0.42) | NOTUMCYP11B1CYP11B2CD38ADH5 | |
| SCHEMBL7459313 | 0.80 | NOTUM (0.37) | NOTUMCNR1CNR2IDO1CYP11B1 | |
| SCHEMBL1362824 | 0.80 | MAPK1 (0.43) | SMN1; SMN2 | |
| SCHEMBL1361453 | 0.80 | CYP3A4 (0.38) | CYP11B1CYP11B2CD38CYP19A1 | |
| SCHEMBL1361686 | 0.79 | NOTUM (0.40) | NOTUMSIRT2CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL1361653 | 0.79 | KDM4E (0.43) | SIRT2CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL7457881 | 0.79 | KDM4E (0.45) | SMN1; SMN2ADH5NAMPT | |
| SCHEMBL7459279 | 0.78 | PKM (0.38) | NOTUMSMN1; SMN2CD38NAMPT | |
| SCHEMBL963990 | 0.77 | SIRT2 (0.40) | NOTUMSIRT2CNR1SMN1; SMN2ADH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067453-B2 | Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-7396848-B1 | oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6605629-B1 | Oxazole derivatives; low toxicity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| US-6498179-B1 | SUCH AS 4-(4-CHLOROPHENYL)-5-(3-(2-METHOXYPHENOXY)PROPYL)-2-(2-METHYL-1 -IMIDAZOLYL)OXAZOLE; INSULIN SECERTION PROMOTING AND BLOOD SUGAR DEPRESSING EFFECT; DIABETES; LOW TOXICITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-0891340-B1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-1206472-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014372-A2 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
| US-6177452-B1 | ANTIDIABETIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0891340-A1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036882-A1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | BDNF, NGF, NTRK2 | NOTUM 2144/4885SIRT2 1453/4885CNR1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.